• Wondering if Boston Scientific at around US$63.82 is offering value or if you are better off waiting on the sidelines? This breakdown focuses squarely on what the current price might imply.
• The stock is up 3.2% over the last 7 days, but still shows a 7.7% decline over 30 days and a 32.3% decline over 1 year, which may indicate shifting views on both its growth potential and risk.
• Recent headlines have focused on Boston Scientific's role in the broader medical device sector and how product approvals, procedural volumes, and reimbursement trends are influencing sentiment. Investors are watching how these themes shape expectations for the business and whether the current share price already reflects them.
• Boston Scientific currently has a valuation score of 5/6, which means it screens as undervalued on most of Simply Wall St's six checks. Next up is a closer look at how different valuation methods stack up and why there may be an even more complete way to think about value by the end of this article.

Approach 1: Boston Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It is essentially asking what all those future dollars are worth in current terms.

For Boston Scientific, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $3.63b. Analyst inputs and extrapolated estimates from Simply Wall St point to projected Free Cash Flow of $6.84b in 2029, with a full set of projections running out to 2035 and then used to infer a long term profile.

When all those projected cash flows are discounted back and summed, the DCF output suggests an intrinsic value of about $112.50 per share. At a recent share price of around $63.82, this implies an intrinsic discount of roughly 43.3%, which screens as materially undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Boston Scientific is undervalued by 43.3%. Track this in your watchlist or portfolio, or discover 57 more high quality undervalued stocks.

Approach 2: Boston Scientific Price vs Earnings

For a profitable company, the P/E ratio is a useful way to think about value because it ties the share price directly to the earnings that owners ultimately rely on. A higher or lower P/E often reflects what the market is willing to pay for each dollar of profit, given expectations and perceived risk.

In simple terms, stronger expected earnings growth and lower risk can justify a higher P/E. Slower growth or higher risk typically points to a lower “normal” P/E range. Boston Scientific currently trades at about 32.7x earnings. That is above the Medical Equipment industry average P/E of 26.8x, but below the peer group average of 41.8x.

Simply Wall St’s Fair Ratio for Boston Scientific is 35.7x. This is a proprietary estimate of what the P/E might be, given the company’s earnings growth profile, industry, profit margins, market cap and risk factors. Because it is tailored to the company, the Fair Ratio aims to be more informative than a simple comparison with peers or the broad industry, which may have very different growth, profitability or risk characteristics.

Comparing the Fair Ratio of 35.7x with the actual P/E of 32.7x suggests the shares are trading below that fair multiple.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Boston Scientific Narrative

Earlier the article mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple way to attach your story about Boston Scientific to the numbers by linking your view on its future revenue, earnings and margins to a financial forecast and a fair value, then comparing that to the current share price using tools on Simply Wall St's Community page that millions of investors already use. Each Narrative updates automatically as new news or earnings arrive. One investor might lean toward the higher fair value around US$122.58 based on more optimistic assumptions, while another anchors closer to the lower analyst price target of US$69.00. Both can clearly see how their different stories translate into different fair values and potential investment decisions.

Do you think there's more to the story for Boston Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.